NCT05293171View on ClinicalTrials.gov

Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

June 1, 2022

Study Completion Date

August 15, 2022

Conditions
Healthy Subjects
Interventions
DRUG

1.25 mg/kg BL-8040 + BL-8040-matching placebo

Administered via subcutaneous (SC) injection

DRUG

2 mg/kg BL-8040

Administered via subcutaneous (SC) injection

DRUG

BL-8040-matching placebo

Administered subcutaneous (SC) injection

DRUG

400 mg Moxifloxacin (1x400 mg tablet)

Administered orally

Trial Locations (1)

85283

Celerion, Phoenix

Sponsors

Lead Sponsor

BioLineRx, Ltd.

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

BioLineRx, Ltd.

INDUSTRY

NCT05293171 - Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects | Biotech Hunter | Biotech Hunter